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ABSTRACT
Objectives: The Restless Legs Syndrome Quality of Life
questionnaire (RLSQoL) assesses the impact of RLS on
daily life, emotional well-being, social life, and work life.
This study investigates its validity and reliability.
Methods: The RLSQoL was tested in 85 American adults
with primary RLS. Patients were also asked to rate symp-
tom severity with the International Restless Legs Scale
(patient-reported version) and report on changes in symp-
toms over the 2-week period.
Results: The RLSQoL summary scale score (range: 0–
100) demonstrated acceptable internal consistency relia-
bility (Cronbach’s alpha = 0.92) and test–retest reliability
(intraclass correlation coefﬁcient = 0.84). All items indi-
cated acceptable item-convergent validity. The RLSQoL
distinguished between groups with mild, moderate, and
severe symptoms (F = 52.22, P < 0.0001). It demon-
strated preliminary responsiveness to changes in RLS
status over 2 weeks (effect size: improvement, 0.25;
deterioration, -0.32), indicating moderate scale changes
consistent with the small clinical change over this time.
Conclusions: These ﬁndings support the conceptual
framework of the RLSQoL. It is a valid and reliable meas-
ure of the impact of RLS on QoL and is responsive to
short-term changes in symptom severity. The RLSQoL
appears to be an appropriate tool for trial-based assess-
ments of treatments for RLS.
Keywords: health status, quality of life, questionnaire,
restless legs syndrome.
Introduction
Restless legs syndrome (RLS) is a movement disor-
der in which a person experiences a strong urge to
move the legs or other extremities while at rest;
symptoms are temporarily at least partly relieved by
movement. Symptoms have a strong circadian pat-
tern: they are worse in the evening and at night and
are often diminished in the morning at the end of
the sleep period. The urge to move is usually accom-
panied by an unpleasant sensation in the affected
limb; the sensation may be described as creeping,
crawling, tingling and pulling or painful, and com-
monly affects sleep [1,2].
Idiopathic RLS can begin at any time of life, even
in early childhood, though the symptoms often
become more frequent, noticeable, and severe with
age [3,4]. When the condition starts early in life
(before the age of 45 years), there is usually an
insidiously slow progression in symptom severity,
but when it starts later in life (over the age of
45 years), the symptoms tend to progress rapidly
before reaching a plateau. Therefore, the most
severely affected individuals are middle-aged and
elderly adults, though young adults are also very
distressed by the condition [5]. Studies of preva-
lence suggest that there may be a signiﬁcant fraction
of older individuals with symptoms of RLS, and the
prevalence is somewhat greater in women than in
men [6]. RLS frequently occurs for the ﬁrst time in
pregnancy or is exacerbated by it. It is also associ-
ated with iron deﬁciency and end-stage renal disease
[6,7].
RLS sufferers commonly report loss of sleep,
with more severely affected individuals sleeping no
more than 4 or 5 hours every night [5] and therefore
suffering complications in daily functioning, includ-
ing problems with concentrating. Sufferers also
report problems with functioning in sedentary
situations, particularly in physically constraining
places, and also in the evenings, when symptoms are
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usually exacerbated. As a result of these problems,
sufferers may have difﬁculties with their jobs, social
life, and recreational activities. Very little informa-
tion is available on the impact of RLS on patient-
reported quality of life (QoL), aside from limited
studies indicating that it is associated with depres-
sion [8,9].
The primary morbidities of RLS involve sleep
loss, extreme discomfort, and disruption of normal
life activities [1]. QoL is therefore reduced and a
primary goal of treatment should be its restoration.
Thus, for this syndrome, assessing QoL becomes
critical for evaluating the clinical signiﬁcance of the
disorder and treatment beneﬁts. Despite the central
role of QoL in RLS, the development of a method
for its assessment has not previously been under-
taken. Reductions in patient’s QoL result partly
from the distinctive symptoms of this disorder
which result in: chronic sleep loss, disruptions to
circadian pattern, and disruptions to sedentary
activities. Thus physical mobility or functioning
would be less likely to be impacted than sleep or
daily activities. The distinctive and somewhat
unique disruption of QoL begs the development of
a responsive RLS-speciﬁc scale. More general scales
will probably detect the disruption of QoL by RLS,
but may also fail to be responsive to the range of life
disruptions and to the remarkable beneﬁts of treat-
ment reported by patients [10]. The lack of an RLS-
speciﬁc QoL scale at the time of this study reﬂected
the nascent development of treatment evaluation
for this disorder. The development of the Restless
Legs Syndrome Quality of Life questionnaire
(RLSQoL; see Appendix) was undertaken to
address the existing lack of a disease-speciﬁc QoL
instrument for this condition. Interest in this issue
has since been emphasized by the separate develop-
ment of other disease-speciﬁc QoL instruments [11–
13].
Any new instrument must undergo psychometric
evaluation to ensure its reliability and validity in
the patient population. The process determines
whether or not the instrument measures the factors
identiﬁed as clinically signiﬁcant, and whetherit can
be used as planned. The aim of this validation proc-
ess is to collect convincing evidence that the instru-
ment utilizes the intended constructs, with which
the measurements reﬂect the QoL of the patients
and that repeated administrations detect changes in
QoL.
The speciﬁc objectives of this study were to assess
the validity and reliability of the recently developed
RLSQoL and its responsiveness to symptom change
over short periods of time.
Methods
Participants
Adults over 21 years old with primary RLS who
were attending a large speciality practice focusing
on RLS and sleep medicine in the United States were
invited to participate. Diagnoses were made by
sleep-medicine specialists; each had been certiﬁed
by the American Board of Sleep Medicine and had
extensive experience in treating RLS. Exclusion cri-
teria included secondary RLS due to pregnancy,
dialysis, iron deﬁciency, anaemia, brain stem stroke,
and neuropathy.
Measures
RLSQoL items were developed with the help of
expert clinicians and patients with RLS. An initial
19-item tool was developed based on the expertise
of four clinical experts specialized in the ﬁeld of
RLS. Four revisions of the questionnaire were made
based on consultation with these clinical experts
who informally solicited opinions from RLS
patients. After consultation with the experts, 13 of
the 19 items were selected to be included in a pilot
study of RLS patients identiﬁed in a primary care
practice who provided a convenience sample of
well-diagnosed RLS patients with a wide range of
severity. In this study, 185 patients completed the
preliminary QoL questionnaire. Ten of the ques-
tions were answered by 98% of the patients, two
by at least 94%, and one related to the work
impact of RLS by 89%. The answers covered the
full range of the response levels for all but one item,
which had no answers for the highest level (relating
to disruption of evening activities, i.e., all of the
time). Opinions about the questionnaire were solic-
ited as part of unstructured interviews with 10 of
these RLS patients. Based on the information from
this study, three items were added to cover more
general daily activities and evening social activities.
In addition, to reduce the failures to answer the
item covering work, a question about work status
was added to serve as a qualiﬁer for completing the
work-related question. Finally, one item with an
exact number answer was supplemented by an
additional question involving a subjective estimate
of the frequency with which RLS made it difﬁcult
to work a full day. This facilitated completion of
the quantitative responses. No items were deleted
at this stage given the shortness of the question-
naire and the adequacy of the responses. In addi-
tion, the wording of the items was adjusted further
to reduce some confusion reported by the patients.
The ﬁnal 18-item RLSQoL assesses how RLS
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impacts patients’ daily activity, morning and
evening activity, concentration, sexual activity, and
work over the previous 4 weeks. Lower scores
indicate lower QoL. The scoring algorithm for the
RLSQoL summary scale score (see Appendix) was
determined based on the results of this psychomet-
ric validation study.
In addition to the RLSQoL, four other question-
naires were administered: demographics, the
International Restless Legs Scale-Patient Version
(IRLS-PV), the Short Form 36 Health Survey (SF-
36), and a brief health status change questionnaire.
Patient demographics included patients’ age, gen-
der, work, and marital status.
The IRLS-PV assesses symptom severity and
impact and was adapted from the clinician-
administered version of the IRLS (IRLS-Investigator
Version [IV]). The IRLS-IV contains 10 items and
has demonstrated reliability and validity [14].
Because of the fact that our study utilized a mail-out,
mail-back design, the IRLS-IV needed to be adapted
so that patients could complete it without the aid of
a clinician. The adaptation resulted in the produc-
tion of the 16-item IRLS-PV to meet these objec-
tives. A 1-week recall was used. Lower scores
indicate less severe RLS [15]; scores may range from
0 to 50. The data from this study were used to val-
idate the IRLS-PV and found to be both reliable and
valid [15]. The IRLS-PV was used to assess RLS
severity: a score of 10–25 was considered to be mild;
a score of 26–35 was considered to be moderate, and
a score of 36–50 was considered to be severe.
The SF-36 is a well-validated and reliable generic
measure of health status and was included as a con-
current validity measure [16]. The SF-36 contains
36 items assessing 8 health dimensions: physical
functioning, bodily pain, general health percep-
tions, role limitations due to physical problems,
social functioning, role limitations due to emotional
problems, vitality, and mental health. A 4-week
recall period was used. The SF-36 was scored as per
the developer’s instructions [16]. Scores range from
0 to 100 and lower scores indicate poorer health
status.
The health status change questionnaire asked the
patients to report their perceptions of any changes
in health status on a 7-point scale over the 2-week
study period. This item was used to assess the sta-
bility of the patients’ health status for test-retest
reliability and to assess responsiveness.
Procedure
The psychometric properties of the RLSQoL were
assessed during an observational, longitudinal 2-
week study conducted at a large speciality practice
focusing on RLS and sleep medicine in the United
States. Those patients who agreed to participate (see
Participants section in Methods) signed an Internal
Review Board-Approved informed consent state-
ment and were then sent the battery of question-
naires twice by mail over a 2-week period. Patients
returned the questionnaires in prepaid postage
envelopes. Around the time of the second assess-
ment, a trained clinical investigator telephoned all
patients who agreed to participate to conduct an
interview  about  changes  in  symptoms  during  the
2-week period. The protocol was reviewed and
approved by the Human Subjects Institutional
Review Board of the Johns Hopkins School of Med-
icine, Baltimore, MD, USA.
Psychometric Analysis
All data processing and analyses were performed
using Statistical Analysis System (SAS) software
(version 8.02). The item-scaling tests were per-
formed using Multitrait Analysis Program for Win-
dows (version 1.0) [17].
The following statistical tests were used:
Kruskal–Wallis and ANOVA tests when comparing
three groups of patients or more; Mann–Whitney,
Wilcoxon and t-tests when comparing two groups
of patients; Wilcoxon signed-rank test and paired t-
test for paired test comparing a change to 0.
Appropriate statistics, such as Cronbach’s alpha,
Pearson, Spearman, and intraclass correlation coef-
ﬁcients (ICCs), were calculated for speciﬁc analyses.
These are described in the relevant sections below.
For all the tests, a signiﬁcance level of 0.05 was
used, unless otherwise indicated.
Construct validity. Exploratory factor analyses
through Principle Component Analysis (PCA) with
Varimax rotation were used to assess the items with
Likert responses in the questionnaire, as we were
trying to determine the scale structure of this new
questionnaire. Exploratory factor analysis may be
conducted if the sample size is at least equivalent to
ﬁve patients per item included in the analysis [18].
Twelve Likert items were to be included in the anal-
ysis; thus, a minimum of 60 people were required
for the analysis. If more than 40% of the variance
was accounted for by the ﬁrst unrotated factor, a
summary scale score may be calculated.
Item-scaling tests. Given the adequate but rela-
tively small sample, the correlation between each
item and the scale, corrected for overlap, was also
assessed to ascertain the item-convergent validity of
the scale (item-scale correlation ≥ 0.4) [19,20].
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Reliability. Internal consistency reliability. Using
the Cronbach’s alpha coefﬁcient/statistic, the inter-
nal consistency reliability was estimated to assess
the extent to which individual items are consistent
with each other. An alpha value of at least 0.70 has
been recommended if the measure is to be consid-
ered reliable [21,22], though reliability coefﬁcients
are susceptible to the number of items within a
scale. Alpha coefﬁcients should be interpreted with
greater caution in scales with fewer items.
Reproducibility (test–retest reliability). Repro-
ducibility of scale scores over a short period of time
is an important psychometric characteristic. To test
this measurement, the RLSQoL was administered
on two separate occasions: at baseline and 2 weeks
later. This interval was considered to be sufﬁciently
short for patients to remain stable and experience
no changes in QoL, while being sufﬁciently long to
avoid memory bias. As recommended in the litera-
ture, the ICC was used to compare the test–retest
QoL assessments, and should be equal to or greater
than 0.70 [21,23].
ICCs were calculated for the total sample and
then for patients who reported stable RLS symp-
toms over the 2-week period. Patients had to com-
pleted the RLSQoL at baseline and at week 2 to be
included in this analysis. ICCs were calculated for
multi-item scores, as well as any single-item meas-
ures, which were not included in multi-item scales
in the event that the single items are to be used in
future studies.
Concurrent validity. The concurrent validity of the
RLSQoL was examined by analyzing correlation
levels between the RLSQoL summary scale score
and the SF-36 summary scales. A correlation of
greater than 0.40 was considered a sufﬁcient crite-
rion to determine concurrent validity for the multi-
item scales and a criterion of 0.30 was acceptable
for the single-item measures. It was hypothesized
that the RLSQoL scale would be signiﬁcantly cor-
related with the SF-36 mental components sum-
mary (MCS) scale because the RLSQoL focuses on
the distress the patient feels due to the RLS symp-
toms. The physical component summary (PCS)
scale focuses primarily on mobility limitations and
pain, which are not included in the RLSQoL
because these are not symptoms consistently
reported by most RLS patients.
Known groups validity. The RLSQoL summary
scale score was compared with the patients’ self-
reported symptom severity based on the overall
score of the IRLS-PV. Patient scores on the IRLS-PV
were used to determine mild (a score of 10–25),
moderate (a score of 26–35), and severe (a score of
36–50)  categories  for  symptoms.  This  scoring
was  a departure from the original, clinician-aided,
self-administered IRLS-IV severity scoring, given
the additional questions that were included in the
summary scale score. Three-way median splits were
used to determine the severity level for the purposes
of this analysis; however, these splits are data-driven
and should not be considered clinical cutoffs. It was
hypothesized that the more severe the RLS, the
worse the QoL scores would be on the RLSQoL.
Responsiveness. QoL changes were compared with
direct reports of health status change by patients.
The effect sizes (ESs) may be calculated by dividing
the change in mean scores from baseline to follow-
up by either the SD of the scores at baseline or the
SD of the change in scores between baseline and fol-
low-up. The ES measurements recommended in the
literature include [23–25]:
1. small change (ES = 0.20);
2. moderate change (ES = 0.50); and
3. large change (ES = 0.80).
The ES in this analysis was calculated as follows:
the difference in mean change in score for patients
showing a change over time (improvement, deteri-
oration) from baseline to follow-up was divided by
the SD of baseline scores for all patients to obtain
an ES [21]. This ES was characterized as small,
moderate or large following the above guidelines
[23–25].
Given the short length of this study, responsive-
ness was assessed only in a preliminary fashion,
using patients’ reports of change in RLS status in
the follow-up telephone interview at week 2 as the
main criterion.
Results
Response Rates and Acceptability
Of 200 surveys mailed to patients with primary RLS
and seen at the clinic in the past year, 85 adults
(aged over 21 years) returned baseline assessments
(a 42.5% response rate). Of these 85 patients, 62
(72.9%) returned the 2-week assessments.
For the RLSQoL, the average amount of missing
data per patient was 0.9 ± 1.1 items. Forty-eight
percent of the patients had no missing data in the
RLSQoL; 25.9% had one item missing; 16.5% had
two items missing; 5.9% had three items missing;
3.5% had four items missing. Because 68.2% of the
patients did not work, they were asked to omit
items related only to work and these items were not
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included in the analysis of missing data. Items 5 and
6, however, which asked how often patients were
late for work or ﬁrst appointments of the day and
how many days they were late, could mostly only be
answered by the patients who were working. These
two items accounted for a signiﬁcant amount of
missing data, with 8 (9.4%) patients not responding
to item 5 and 25 (29.4%) patients not responding to
item 6.
For the two sexual activity items (items 11 and
12), two patients did not respond to item 11 and six
patients did not respond to item 12 (i.e., missing
data). In addition, 15 (17.6%) patients ticked the
“prefer not to answer” box for item 11 and 18
(21.2%) patients ticked this box for item 12; for
those patients that chose the response option “pre-
fer not answer,” their responses were not included
in  the  calculation  of  missing  data  because  they
did actually respond to the question. The majority
(≥75%) of patients who omitted answers or indi-
cated they preferred not to answer the sexual items
were aged over 65 years. These results were
expected for those people for whom sexual activity
may not be applicable or relevant.
Demographic and Clinical Characteristics of  
the Sample
Baseline  socio-demographic  data  for  the  sample
are shown in Table 1. The majority of the sample
(63.5%) were women and the mean age (± SD) was
62.4 ± 14.0 years. The majority of patients (71.6%)
lived with a partner. Approximately 36% of the
patients were in paid employment (full- or part-
time) and, of those, 86.7% worked day shifts.
The baseline clinical characteristics of the sample
are summarized in Table 2. The mean age (± SD)
when RLS symptoms ﬁrst appeared was 36.6 ± 19.6
years. On average, daily symptoms began to occur
approximately 10.5 ± 10.3 years after ﬁrst noticing
the feelings or movements of RLS. Within the
4 weeks before questionnaire completion, 95.0%
reported experiencing RLS feelings daily. For those
Table 1 Baseline sociodemographic data for recruited
population
Characteristic
Total 
(N = 85)
Age (year) (n = 85)
Mean 62.4
SD 14.0
Range 26–87
Gender, n (%) (n = 85)
Male 31 (36.5)
Female 54 (63.5)
Marital status, n (%) (n = 76)
Living alone 14 (17.3)
Living with partner 58 (71.6)
Other 9 (11.1)
Work status, n (%) (n = 76)
Full-time 23 (30.3)
Part-time 4 (5.3)
Unemployed 2 (2.6)
Volunteer 1 (1.3)
Retired 33 (43.4)
Homemaker 5 (6.6)
Other 8 (10.5)
Work shift, n (%) (n = 30)
Day shift 26 (86.7)
Second shift 1 (3.3)
Other 3 (10.0)
Table 2 Baseline clinical characteristics for recruited
population
Characteristic
Total 
(N = 85)
Age when ﬁrst noticed symptoms (year) (n = 83)
Mean 36.6
SD 19.6
Range 0–80
When symptoms began to occur daily (years after 
symptoms ﬁrst occurred)
(n = 72)
Mean 10.5
SD 10.3
Range 0–41
RLS symptoms experienced daily, n (%) (n = 60)
Yes 57 (95.0)
No 3 (5.0)
RLS symptoms experienced in the last 4 weeks, n (%) (n = 72)
Yes 57 (79.2)
No 15 (20.8)
Number of  days symptoms occurred per month 
(for those without daily symptoms and responding 
to question)
(n = 15)
Mean 7.5
SD 6.3
Range 0–20
Missing data 59
Time when RLS symptoms started (after 11 AM when 
at rest)*, n (%)
(n = 68)
11 AM–noon 9 (13.2)
1 PM-3:30 PM 15 (22.1)
4 PM-5:30 PM 15 (22.1)
6 PM-7 PM 16 (23.5)
8 PM-11 PM 9 (13.2)
2 AM-6 AM 4 (5.9)
Time when RLS symptoms stopped,* n (%) (n = 51)
Midnight-5 am 21 (41.2)
6 AM–noon 11 (21.6)
1 PM-6 PM 10 (19.6)
9 PM-11:30 PM 9 (17.6)
Number of  hours per day with RLS symptoms, n (%) (n = 84)
None of  the time 7 (8.3)
< 1 hours 8 (9.5)
1–2 hours 20 (23.8)
3–8 hours 41 (48.8)
≥ 9 hours 8 (9.5)
Patients’ general health perceptions, n (%) (n = 84)
Excellent 5 (6.0)
Very good 24 (28.6)
Good 33 (39.3)
Fair 17 (20.2)
Poor 5 (6.0)
Medication use, n (%) (n = 79)
Yes 73 (92.4)
No 6 (7.6)
*Patients were asked to identify the time when symptoms started/stopped;
missing time periods indicate that no patients identiﬁed these periods as times
when symptoms started/stopped.
RLS, restless legs syndrome.
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who did not experience RLS feelings daily, RLS
symptoms were experienced on an average of
7.5 ± 6.3 days per month. Twenty-nine (34.6%)
patients reported either excellent or very good
health, 33 (39.3%) good health, and 22 (26.2%)
either fair or poor health. Seventy-three (92.4%)
patients reported taking treatment for their RLS,
and six (7.6%) reported taking no medication.
Psychometric Results
Construct validity. The factor analysis (PCA) was
performed on the items with Likert responses in the
RLSQoL. Three factors were identiﬁed (daily activ-
ities, morning activities, and sexual activities).
The eigenvalue was 6.1, with a cumulative vari-
ance of 51% in the ﬁrst unrotated factor, indicating
that the RLSQoL can be calculated as a summary
scale score with the possibility of reporting the three
factors separately. The eigenvalues and cumulative
variances for the second and third factors were 1.54
(13%) and 1.01 (8%), respectively. However, given
that the ﬁrst factor was so large and that some clin-
ically relevant items loaded on two factors, we
decided to focus our analysis and interpretation on
the summary score.
Based on the missing data and factor analysis
results, it was decided that the RLSQoL summary
scale would include items 1–5, 7–10, and 13. Given
the large number of patients who were found to be
not currently working, the work-speciﬁc items were
excluded (items 14–18) from the summary scale
score. In addition, item 6, an item related to work
activities, was excluded from the summary scale
because of the high rates of missing data. Interest
and disturbance in sexual activity (items 11 and 12)
were excluded because many patients preferred not
to answer these questions. If these sexual items had
been included in the summary scale score, it would
have artiﬁcially inﬂated the potential for missing
data (if a “prefer not to respond” answer was con-
sidered missing) or artiﬁcially inﬂated the score (if a
“prefer not to respond” answer was considered as
“no limitations”). Nevertheless, it was decided that
each item excluded from the summary score may
still provide useful information in larger scale stud-
ies. For this reason, the items excluded from the
summary score were still retained as part of the
questionnaire as a whole, until further analyses of
their usefulness in larger studies, with a broader
population of RLS sufferers, including sexually
active or working patients, could be assessed.
Item-scaling tests. For the RLSQoL summary scale,
all items met or exceeded the test for item-conver-
gent validity (r ≥ 0.4). Item-scale correlations
ranged from 0.5 to 0.9.
For the RLSQoL summary scale, 1.2% of the
patients reported the lowest or worst possible scores
and 3.5% reported the highest or best QoL scores.
Thus, the ﬂoor and ceiling effects were minimal and
acceptable for the summary scale score (< 5%).
Reliability
1. Internal consistency. For the RLSQoL summary
scale, the Cronbach’s alpha reliability coefﬁ-
cient was 0.92, exceeding the minimum crite-
rion of 0.70.
2. Test–retest reliability. The mean difference
between baseline and week 2 was -0.1
(SD = 15.7) for the total sample. This difference
was minimal and not statistically signiﬁcant
(t = -0.05, P = 0.96). Similarly, in patients with
stable symptoms (n = 33), as reported by the
patients in the health status change question-
naire, the mean difference between baseline and
week 2 was -0.1 (SD = 15.0).  This  difference
was  also  minimal  and not statistically signiﬁ-
cant (t = -0.04, P = 0.97). The ICCs were above
the minimum standard of 0.70 for test–retest
reliability for the RLSQoL summary scale
(0.79) in the total sample and for patients with
stable symptoms (0.84).
ICCs for those items not included in the sum-
mary scale score met or exceeded the tests for repro-
ducibility (ICC range: 0.7–0.97), with the exception
of items 15 (ICC = 0.69) and 18 (ICC = 0.5). The
former is just below the prespeciﬁed test limit crite-
rion and the latter item may be expected to vary
over time as it relates to a potentially variable meas-
ure (i.e., hours of work cut back).
Concurrent validity. The RLSQoL summary scale
score was correlated most highly with the SF-36
MCS scale, indicating that the better the QoL, as
rated by the RLSQoL, the better the mental health
status was, as rated by the SF-36 (r = 0.5, P
£ 0.0001). Correlations between the RLSQoL sum-
mary scale and the SF-36 PCS scale were not signif-
icant (r = 0.1, P = 0.3).
Of those items not included in the RLSQoL sum-
mary scale (items 6, 11, 12, 14–18), only item 17
(“on average, how many hours per day did you
work?”) was signiﬁcantly correlated to the SF-36
PCS scale (r = 0.4, P = 0.04). Five items were signif-
icantly correlated to the SF-36 MCS scale: items 6
(r = 0.5, P = 0.0002), item 11 (r = 0.3, P = 0.003),
Validation of the RLSQoL Questionnaire 163
item 15 (r = 0.4, P = 0.0001), item 16 (r = 0.5,
P = 0.004), and item 18 (r = 0.6, P = 0.0002).
Known groups validity. Figure 1 compares RLSQoL
summary scale scores with the patients’ reports of
RLS severity, based on the patients’ scores for the
IRLS-PV. The RLSQoL summary scale score was
able to distinguish between patients whose symp-
toms were mild, moderate, or severe, indicating the
known groups validity of the RLSQoL (F = 52.22,
P < 0.0001).
Responsiveness. For the RLSQoL summary scale,
preliminary responsiveness was measured by assess-
ing the distribution of scores at baseline and at week
2, and then assessing the mean difference between
the two scores for patients whose symptoms were
worse, stable, or improved, as deﬁned by the coad-
ministered health status change questionnaire item
(Fig. 2). Patients who reported that their RLS symp-
toms had worsened over the 2-week period had
slightly higher baseline QoL scores than patients
who reported stability or improvement in RLS
symptoms over the 2-week period. At the 2-week
assessment, however, QoL scores were worse for
those patients whose symptoms had worsened over
the 2-week period compared with those patients
whose symptoms had improved or remained stable.
Indeed, though the sample sizes were too small to
detect statistically signiﬁcant differences, the initial
results were promising, as the trends were in the
correct  direction.  That  is,  patients  reporting
worse symptoms at the 2-week assessment reported
poorer QoL than those patients who had stable or
improved symptoms. Conversely, improved patients
reported better QoL scores.
When examining mean difference scores, trends
were in a similar direction, with patients whose
symptoms had become worse demonstrating a
decrease in scores (mean change = -7.92, SD = 9.2,
indicating worse QoL), patients with stable symp-
toms demonstrating similar scores (mean
change = -0.09, SD = 2.6, indicating fairly stable
QoL), and patients with symptoms that improved
reporting an increased QoL score (mean
change = 6.18, SD = 4.8, indicating better QoL;
Fig. 2). Finally, the ESs for both the improved and
worsened groups indicated a small-to-moderate
change (0.25 and -0.32, respectively) (Fig. 2).
Despite the small sample sizes within each group,
these results demonstrated preliminary responsive-
ness for the RLSQoL scale.
This test was also performed for the single-item
assessments not included in the summary scale
score. These results also suggested small-to-moder-
ate ESs (data available from authors upon request).
Discussion
Establishing the psychometric properties of a QoL
measure is an essential part of its development. If
such measures are to be useful tools in both the clin-
ical and research settings, they must have good reli-
ability and validity, and be responsive to change.
The  work  reported  here  conﬁrms  the  psychomet-
ric integrity of the RLSQoL, a newly developed
patient-reported measure for assessing QoL speciﬁc
to RLS.
Based on the results of this evaluation, scaling
assumptions are satisfactorily met for the summary
scale of the RLSQoL based on 10 of the 18 items.
While the RLSQoL proved to be psychometrically
robust, further analyses of potential subscales could
be examined in a larger study. The results provide
evidence of the psychometric properties of the
RLSQoL within the RLS population studied, and at
least support its use in RLS patients living in the
USA. Its use in other populations needs to be deter-
mined by further empiric investigation. Findings
from this study offer support for the conceptual
framework of the instrument and underscore the
Figure 1 Known groups validity: mean Restless Legs Syndrome
Quality of  Life questionnaire scores by severity, as rated by patients on
the International Restless Legs Scale-Patient Version.
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value of measures that evaluate relevant issues sur-
rounding the QoL of RLS sufferers.
In this analysis, we have focused primarily on the
multi-item summary scale score of the RLSQoL.
The sexual activity items were consistently prob-
lematic; however, the variance in response would
suggest that it is useful to include these questions in
the ﬁnal version of the questionnaire, particularly
for those patients for whom the topic is relevant and
applicable. It may also be useful to assess each item
to ascertain which distinguish best among RLS
severity levels (e.g., using Rasch analysis and struc-
tural equation modeling, though a much larger sam-
ple size would be needed for such an analysis).
Given the extensive number of tests performed on
the data and the relatively small sample size, it was
most appropriate to use the multi-item summary
scale score to initially examine the psychometric
properties of the RLSQoL. In this way, maximum
power is achieved by using the minimal number of
variables. Nevertheless, test–retest reliability and
concurrent validity results for the single items not
included in the summary scale have been provided
in the event that these items may prove useful in a
more heterogenous population. Further testing of
the single-item measures, in terms of responsive-
ness, will be carried out at a later date on a larger
sample.
All of the items included in the RLSQoL sum-
mary scale score were found to be psychometrically
robust. The RLSQoL summary scale score had high
item-convergent validity, acceptable levels of inter-
nal consistency reliability, and all had negligible
ﬂoor and ceiling effects. In addition, test–retest reli-
ability, concurrent validity, known group’s validity,
and preliminary responsiveness were demonstrated
for the questionnaire.
The RLSQoL was more highly correlated with
the SF-36 MCS score than the PCS score; this might
have been expected because the PCS scale focuses
primarily on mobility limitations and pain, which
are not included in the RLSQoL. In addition, in the
RLSQoL, some items focused on symptom-related
distress, which could explain this ﬁnding.
A clear pattern emerged with regard to the
known group’s validity of the RLSQoL. The
RLSQoL was able to distinguish between patients
whose symptoms varied in severity based on the
IRLS-PV scores. The degree of differences between
the three severity groups was quite substantial, with
an average of 20 points or more. However, it is
important to note that the IRLS-PV, while assessing
RLS severity, also includes some items that assess
the impact of symptoms. Thus, the symptom-
impact items of the IRLS-PV may contribute sub-
stantially to the differences between scores.
The fact that the RLSQoL was able to distinguish
not only between severity groups but also between
those patients who reported improved and wors-
ened symptoms over a 2-week period, suggests that
differences may be assessed using this measure in
long-term treatment trials. In considering our ﬁnd-
ings, it is important to bear in mind that the
RLSQoL was developed as a longitudinal measure
for use in clinical trials. We would argue that
patients’ responses to these scales are likely to
change over time depending on the clinical course of
their RLS problems and, potentially, depending on
their age. In this preliminary psychometric valida-
tion, no extensive longitudinal data were available,
though the preliminary responsiveness testing over
the 2-week period was extremely encouraging. Fur-
ther testing in a controlled study of intervention
methods is warranted.
Based on this initial validation of the RLSQoL,
we recommend that the ﬁnal version be used in con-
junction with continued research. We propose con-
certed efforts be made in ﬁve complementary areas:
1. evaluating the potential for subscales from the
RLSQoL;
2. evaluating the responsiveness of the RLSQoL
scale and item scores to changes over time in
larger sample sizes over a longer period of time
in intervention studies;
3. using a causal indicator model to assess appro-
priate constructs in heterogeneous populations
with this chronic condition;
4. assessing the psychometric properties of the
RLSQoL in foreign cultures; and
5. incorporating use of the RLSQoL into routine
clinical assessments and trials to better under-
stand the meaning and interpretation of indi-
vidual patient scores.
Addressing  these  issues  represents  a  tremen-
dous challenge and will require a timely, well-
orchestrated effort. Potentially, however, the
RLSQoL could lead to an appreciably greater under-
standing of RLS, its diagnosis, and its treatment.
Source of ﬁnancial support: This study was supported
in part by NIH grant 1R01 AG-16362 and by
GlaxoSmithKline.
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Appendix: RLS Quality of Life Questionnaire*
The following are some questions on how your Restless Legs Syndrome might affect your quality of life.
Answer each of the items below in relation to your life experience in the past 4 weeks. Please mark only one
answer for each question.
In the past four weeks:
1. How distressing to you were your restless legs?
 Not at all  A little  Some  Quite a bit  A lot
2. How often in the past 4 weeks did your restless legs disrupt your routine evening activities?
 Never  A few times  Sometimes  Most of the time  All the time
3. How often in the past 4 weeks did restless legs keep you from attending your evening social activities?
 Never  A few times  Sometimes  Most of the time  All the time
4. In the past 4 weeks how much trouble did you have getting up in the morning due to restless legs?
 None  A little  Some  Quite a bit  A lot
5. In the past 4 weeks how often were you late for work or your ﬁrst appointments of the day due to restless
legs?
 Never  A few times  Sometimes  Most of the time  All the time
6. How many days in the past 4 weeks were you late for work or your ﬁrst appointments of the day due to
restless legs?
Write in number of days: 
7. How often in the past 4 weeks did you have trouble concentrating in the afternoon?
 Never  A few times  Sometimes  Most of the time  All the time
8. How often in the past 4 weeks did you have trouble concentrating in the evening?
 Never  A few times  Sometimes  Most of the time  All the time
9. In the past 4 weeks how much was your ability to make good decisions affected by sleep problems?
 None  A little  Some  Quite a bit  A lot
10. How often in the past 4 weeks would you have avoided traveling when the trip would have lasted more
than two hours?
 Never  A few times  Sometimes  Most of the time  All the time
11. In the past 4 weeks how much interest did you have in sexual activity?
 None  A little  Some  Quite a bit  A lot
 Prefer not to answer
12. How much did restless legs disturb or reduce your sexual activities?
 None  A little  Some  Quite a bit  A lot 
 Prefer not to answer
13. In the past 4 weeks how much did your restless legs disturb your ability to carry out your daily activities,
for example carrying out a satisfactory family, home, social, school or work life?
 Not at all  A little  Some  Quite a bit  A lot
14. Do you currently work full or part time (paid work, unpaid or volunteer)?
(mark one box)
 YES If Yes please answer questions #15 through #18
 NO, because of my RLS – Please go to the next page
 NO, due to other reasons – Please go to the next page
15. How often did restless legs make it difﬁcult for you to work a full day in the past 4 weeks?
 Never  A few times  Sometimes  Most of the time  All the time
16. How many days in the past 4 weeks did you work less than you would like due to restless legs?
Write in number of days: 
17. On the average, how many hours did you work in the past 4 weeks?
Write in number of hours per day: 
18. On days you worked less than you would like, on average about how many hours less did you work due
to your restless legs.
Write in number of hours per day: 
*Copyright 2002, Richard Allen; reproduced with kind permission.
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Scoring
A summary score can be calculated for the RLS quality of life questionnaire based on the following items:
1–5, 7–10 and 13. All items must be recoded such that 1 equals most severe and 5 equals least severe, so that
lower scores indicate worse quality of life. The score is then transformed to a 0–100 score using the fol-
lowing algorithm:
([Actual raw score––lowest possible raw score]/Possible raw score range) ¥ 100.
If more than two items are missing from the summary scale, the summary scale score cannot be calculated
and is set to missing. If one or two items from the summary scale are missing, then a person-speciﬁc estimate
is substituted for that missing item. This person-speciﬁc estimate is the average score, across the completed
items in the summary scale, for that respondent.
Items 6 and 16–18 are scored as continuous variables, as written by the patient. For items 6 and 16, the
minimum number of days is 0 and the maximum number of days is 28. For items 17 and 18, the minimum
number is 0 hours and the maximum number is 24 hours. If the response to one of these items is missing or
out of range, than that item is set to missing. Items 14–18 are work-related items, thus if patients reply “2”
or “3” to item 14, they are not expected to reply to items 15–18. Thus, the missing data rates for items 15–
18 will be artiﬁcially inﬂated.
Items 11, 12 and 15 should be scored as categorical variables. Finally, item 14 can also be treated as a cat-
egorical variable as follows: “yes” = 1; “no, because of my RLS” = 2; “no because of other reasons” = 3. If
a response to one of these items is missing, then no score can be calculated for that item.
